Free NewsletterPro Login

Warning: Undefined variable $stocks in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: Undefined variable $funds in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472
/* the link was here */
×
Free investor livestream — Nov 17

How To Use ChatGPT & Claude To Research Stocks Like A Pro

01
The prompt we use to break down any stock
02
How to fact-check what AI tells you
03
How to compare two stocks in minutes

Lilly's combo of eloralintide plus low-dose tirzepatide tops high-dose tirzepatide in mid-stage study

Published Sep 30, 2026
Share:
Summary:
  • In a 48-week Phase 2 trial in people with obesity and Type 2 diabetes, Eli Lilly's eloralintide paired with a lower dose of tirzepatide led to greater weight loss than tirzepatide at 15 milligrams alone.
  • The most intensive combo arm delivered up to 23.3% average weight reduction (about 54 pounds) and trimmed A1C by as much as 2.9% on average.
  • Lilly says it aims to kick off Phase 3 testing by year end and also stated plans to move the combo into Phase 3 by the end of 2026, including a single-injection co-formulation.

The headline numbers

Lilly's 48-week Phase 2 readout hit its main goals and showed the pairing outperformed high-dose tirzepatide alone on weight loss. The top combo dose - 9 milligrams of eloralintide plus 15 milligrams of tirzepatide - produced up to 23.3% average weight loss, roughly 54 pounds. By comparison, participants on tirzepatide 15 milligrams alone lost 14.8% on average, or 34.4 pounds. Eloralintide by itself delivered up to 12.3% average weight loss, or 28.6 pounds.

Glycemic control improved too. The combination cut A1C by as much as 2.9% on average, versus up to 2.4% with higher-dose tirzepatide alone and up to 1.4% with eloralintide alone.

Lilly said these results build on earlier signals: in a Phase 1 study, participants who received 3 milligrams of eloralintide on top of 5 milligrams of tirzepatide saw an average 17% reduction in body weight across 16 weeks in adults with obesity, versus 10% with 5 milligrams of tirzepatide alone.

Why stacking these hormones could be a winning play

The regimen marries eloralintide, which targets amylin - a pancreatic hormone that helps regulate appetite and the feeling of fullness - with a reduced amount of tirzepatide, the compound used in Zepbound and Mounjaro. Tirzepatide acts on two gut hormones, GLP-1 and GIP. Lilly's bet: engaging all three pathways may curb hunger more effectively and drive deeper weight loss.

"Patients may not get what they need from a drug like tirzepatide," said Ken Custer, president of Lilly Cardiometabolic Health. "They may not get what they need from a drug like a eloralintide on its own. The ability to combine them together and provide even greater weight loss - that's definitely one obvious" benefit. He added, "This very physiological approach of combining GLP-1, GIP, and amylin, which are three nutrient-stimulated hormones that your body releases naturally in response to food and promotes satiety, putting those things together may just make for a drug that is broadly used." Custer also said the combo could "turn out to be a really winning approach."

Safety, dropouts, and what's next

As effective as the combo looked, tolerability will be watched closely. Side effects occurred more often in the combination groups than with tirzepatide alone or eloralintide alone. The most common issues were gastrointestinal, generally mild to moderate, and tended to show up when doses were increased.

Stopping treatment due to side effects happened more in the combo arms, ranging from 10.8% to 27% depending on dose, versus 2.9% with tirzepatide alone. Up to 10.8% of people on eloralintide alone discontinued, compared with 16.7% on placebo. Custer urged caution on reading too much into Phase 2 discontinuations, noting the highest tirzepatide dose also saw around 25% discontinuation in a 2018 mid-stage study: "It's probably not the best indicator of the tolerability of a medicine," he told CNBC.

The money story behind the headlines is usually the part that matters. Join Market Briefs free and get it every morning.

"We do things in Phase 1 and Phase 2 to test what the molecule can do from an efficacy perspective. We also learn from those studies about how we should administer them, and then we make changes. We do this every time." He said Lilly will refine dosing in Phase 3 and "we expect that we'll end up with a very favorable balance of efficacy and tolerability."

Lilly expects to start Phase 3 on the regimen near the close of the year, and on Wednesday it added that the combo is slated to enter Phase 3 by the end of 2026. The company is developing a co-formulation so patients could get both medicines in a single injection in Phase 3.

The competitive lane and why it matters for your money

The findings were shown at the European Association for the Study of Diabetes meeting in Milan, Italy. Ahead of the readout, some analysts framed Lilly's program as a head-to-head concept with Novo Nordisk's next-wave CagriSema, which brings together amylin and GLP-1 mechanisms. Leerink Partners' David Risinger called eloralintide a "mega-blockbuster" prospect and said it likely has "much greater market potential than the Street currently realized," pointing to "millions" of patients who did not get results on current GLP-1s or could not tolerate them. He also noted the combo could be an alternative to Lilly's other advanced obesity candidate, retatrutide, which targets GLP-1, GIP and glucagon and has delivered some of the highest weight-loss levels seen in trials.

One more note from Lilly's materials: the company pointed to signage at a groundbreaking for its pharmaceutical manufacturing campus located in Generation Park in Houston, Texas, on Monday, Sept. 21, 2026.

If you care about where obesity care is heading, watch two near-term markers: how Lilly tunes dosing in Phase 3 and whether the single-shot co-formulation smooths side effects without giving up efficacy. Those will shape real-world uptake and, eventually, revenues that can move a stock - and shape where new therapies land on your insurance form.

Understanding what moved a market beats knowing that it moved. Get the free Market Briefs daily newsletter and follow the drivers.

Disclosure

Recent News

1 2 3 … 129

Get Market Briefs delivered to your inbox every morning for free!

No fluff. No noise. No politics. Just finance news you can read in 5 minutes.

Blogs

November 16, 2026
The $40 Trillion National Debt: Trump's 4-Part Plan to Make It Feel Smaller
  • The national debt is above $40 trillion, and the Federal Reserve has gone from sending Washington its profits to losing money.
  • President Trump's four-part plan leans on shorter-term debt, stablecoin companies buying Treasuries, a bigger balance sheet and government stakes in private companies.
  • The goal is to outgrow the debt, not pay it off, so Jaspreet Singh points investors to the seven industries where Washington wants growth.
Read More
November 16, 2026
The Fed Is Talking About a Jumbo Interest Rate Hike. It Has No Easy Way Out
  • The Fed makes its next rate decision on December 9 and is now talking about jumbo interest rate hikes of 0.5%, though one in December looks unlikely.
  • Washington will pay a record $1.05 trillion in interest this year on $40 trillion of debt, and that debt resets at higher rates as the Fed hikes.
  • Jaspreet Singh's five moves are to pay down variable-rate debt, earn interest on your savings, know which stocks feel the pressure, look at value and hedge.
Read More
November 16, 2026
Buying on Margin Is at a Record High. Here's the Risk for the Stock Market
  • Margin debt, the money investors borrow to buy stocks, is at a record of around 4.6% of GDP, up from 3.9% in 2021.
  • ETF money has more than tripled in five years to 7% of GDP, while corporate buybacks and 401(k) money sit below their earlier peaks.
  • Margin calls and panic selling can make the next downturn deeper, so Jaspreet Singh keeps buying broad market funds and says most investors should skip margin debt.
Read More
November 16, 2026
Housing Prices Are Falling. Buying a House Still Isn't Cheaper
  • Housing prices have fallen for four straight weeks, but mortgage rates around 7.2% keep the monthly payment about where it was in 2023.
  • Talk of a jumbo Fed rate hike and a plan to sell Fannie Mae and Freddie Mac on the stock market could both push mortgage rates higher.
  • Briefs Finance CEO Jaspreet Singh treats a house as a liability: buy within your budget and let your investments build the wealth.
Read More
November 14, 2026
Nvidia News: Jensen Huang Is Out, and the "Bank" Behind American AI Just Lost Its Founder
  • Jensen Huang is out at Nvidia over affairs with multiple people, and the company he founded has been the bank of American AI, with about $30 billion into OpenAI and $10 billion into Anthropic.
  • A hotter-than-expected inflation report has Fed officials talking about a possible 0.5% hike in December, and gold, silver, and bitcoin fell on the news.
  • President Trump said the US may not need a deal with Iran, keeping oil prices and inflation risk high. Jaspreet Singh breaks down what it all means for AI stocks and your portfolio.
Read More
November 14, 2026
Record Highs, a 57-Year Low in Jobless Claims, and a Stock Market Bubble: Inside the Weirdest Market in History
  • Stocks are booming at the fastest pace in years, jobless claims just hit a 57-year low, and most investors still feel like nobody is hiring.
  • The Fed is protecting the dollar over the economy, oil swings on every Iran headline, and a few AI companies are carrying an S&P 500 where four of five stocks sit in a correction.
  • Jaspreet Singh explains why circular financing between Nvidia, OpenAI, Anthropic, and SpaceX rhymes with 2008's house of cards, and how his three investing pillars handle a stock market bubble.
Read More
November 14, 2026
Is a Recession Coming? The Fed Just Made a U-Turn It Has Only Made Twice in 60 Years
  • The Fed has raised rates, cut them, then raised them again only twice in the last 60 years, and both times the economy fell into a recession and stocks crashed.
  • The same stop-and-go cycle is playing out now, with one big difference: US debt is 125% of GDP today versus about 30% in 1980.
  • In the 1970s gold rose roughly 24x, real estate 157%, stocks lagged, and cash lost half its value. Jaspreet Singh lays out five assets to consider before the next flip.
Read More
November 14, 2026
The 2027 Tax Brackets Are Out: How Some Investors Can Earn $135,300 and Pay $0
  • The IRS 2027 tax plan keeps the same seven rates but widens every bracket and lifts the married-filing-jointly standard deduction to $33,200.
  • The 0% long-term capital gains bracket rises to $102,100, so a household living on $135,300 of investment income could owe $0 in federal income tax.
  • C corporations still pay 21%, small businesses keep the 20% QBI deduction, and the 401(k) limit climbs to $25,500 with an $8,500 catch-up for investors over 50.
Read More
November 14, 2026
Rare Earth Stocks: Why China's January 2027 Ban Could Be the Opportunity of the Decade
  • China plans to block rare earth exports to the US on January 10, 2027, and the US produces effectively zero of the 17 metals that go into phones, cars, dishwashers, and missiles.
  • When China cut off Japan in 2010 and squeezed Germany from 2015, some rare earth prices jumped 18x and 15x, and one rare earth company went bankrupt while another soared.
  • Washington is already putting billions into MP Materials, Vulcan, and a stockpile called Project Vault, and Jaspreet Singh walks through how investors can get exposure to rare earth stocks and ETFs.
Read More
November 14, 2026
Divided Government Just Changed Where the Money Moves: 5 Market Shifts After the Midterms
  • Democrats took control of Congress, setting up a divided government with a Republican White House, and the biggest spender in the economy is about to change where it spends.
  • The day after the election the market had one of its best days of 2026 while AI stocks, Tesla, and SpaceX fell and clean energy, healthcare, treasuries, gold, and silver rose.
  • Jaspreet Singh maps the five places money is already moving and the history that says stocks rose in the 12 months after each of the last 19 midterms.
Read More
1 2 3 … 33
Share via
Copy link